Hormone Effects on Brain Blood Flow
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how sex and sex hormones affect blood flow in the brain among healthy young adults. Participants will receive various treatments, including testosterone gel (a form of testosterone), estradiol, or a placebo, to assess their impact on brain blood flow. The study includes several groups to compare the effects of hormone suppression and hormone add-back. It suits healthy individuals who completed Phase 1 of Study 2020-0336, are between 18-40 years old, and do not have conditions like high blood pressure or diabetes. As a Phase 4 trial, the treatments are already FDA-approved and proven effective, aiming to understand how they benefit more patients.
Will I have to stop taking my current medications?
The trial requires that women stop taking hormonal birth control at least one month before the study if it's used for contraception only. Other medications, especially cardiovascular ones, may also need to be stopped, as their use is listed as an exclusion criterion.
What is the safety track record for these treatments?
Research has shown that indomethacin, one of the treatments in this trial, is well-studied. In healthy adults, it can cause short-term changes in blood flow to the brain, but these effects typically last less than a week, indicating the drug is generally safe for short-term use. Some individuals might experience common side effects like an upset stomach or dizziness.
Estradiol and testosterone gel are also part of this study. Both have been safely used for other health conditions. Estradiol, a type of estrogen, plays a crucial role in many body functions. Testosterone gel helps increase testosterone levels. These treatments are usually well-tolerated, though some people might experience mild side effects like skin reactions or mood changes.
Anastrozole and Orilissa adjust hormone levels. Anastrozole is often used in breast cancer treatment, while Orilissa helps with endometriosis pain. They are generally safe, but some users may experience side effects like hot flashes or tiredness.
As this is a phase 4 trial, these treatments have been tested in large groups before, providing extensive information about their safety. While side effects can occur, these treatments are generally considered safe for short-term use in healthy adults.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about these treatments because they investigate how different hormones and hormone blockers like Anastrozole, Estradiol, Indomethacin, Orilissa, and Testosterone gel affect brain blood flow. Unlike traditional treatments that primarily focus on hormone replacement or suppression in isolation, this study looks at the combined impact of adding or suppressing multiple hormones simultaneously. This approach could offer new insights into how hormonal changes influence brain function and potentially lead to breakthroughs in managing conditions related to hormone fluctuations. By exploring these unique interactions, researchers hope to uncover new ways to optimize hormone therapies for better brain health outcomes.
What evidence suggests that this trial's treatments could be effective for influencing cerebral blood flow?
Research has shown that treatments like Anastrozole, Estradiol, Indomethacin, Orilissa, and Testosterone gel can affect blood flow in the brain. In this trial, participants will receive different treatments in separate arms. For instance, Indomethacin, administered to some participants, quickly reduces blood flow in the brain after intake. This reduction often links to more efficient oxygen use by the brain. Estradiol and Testosterone, included in other treatment arms, may alter blood flow patterns due to their role in hormone regulation. Anastrozole and Orilissa, also studied in this trial, affect hormone levels and are being explored for their potential to change brain blood flow. These treatments aim to understand how hormones impact brain activity and blood flow in healthy adults.678910
Who Is on the Research Team?
William G Schrage, PhD
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 18-40 who want to help understand how sex and hormones affect brain blood flow. The study will include an equal number of males and females, totaling 26 participants.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Hormone Suppression
Participants undergo hormone suppression using Orilissa and Anastrozole, followed by MRI visits to assess CBF under hypoxia and hypercapnia conditions.
Hormone Add-Back
Participants receive sex hormone add-back (testosterone for males, estradiol for females) and undergo MRI visits to assess CBF under hypoxia and hypercapnia conditions.
Follow-up
Participants are monitored for safety and effectiveness after the completion of MRI visits.
What Are the Treatments Tested in This Trial?
Interventions
- Anastrozole
- Estradiol
- Indomethacin
- Orilissa
- Testosterone gel
Trial Overview
The study tests the effects of testosterone gel, placebo, Anastrozole (blocks estrogen production), Orilissa (alters hormone levels), Indomethacin (a pain reliever), and Estradiol (a form of estrogen) on brain blood flow in response to stress.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Participants drug (placebo vs Indo) are randomized prior to first set of MRI visits, while experiencing hormone suppression.
Participants drug (placebo vs Indo) are randomized prior to second set of MRI visits, while experiencing hormone add-back.
Participants drug (placebo vs Indo) are randomized prior to first set of MRI visits, while experiencing hormone suppression.
Participants drug (placebo vs Indo) are randomized prior to second set of MRI visits, while experiencing hormone add-back.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Published Research Related to This Trial
Citations
Indomethacin: a review of its cerebral blood flow effects ...
Case series involving severe TBI patients suggest that IND i.v. boluses of 30-50 mg reduce ICP by 37%-52%, reduce CBF by 22%-26%, with a modest 14% increase in ...
Effects of indomethacin on cerebral blood flow and oxygen ...
Indomethacin induced a highly significant decrease in CBF during hypercapnia, demonstrating that the barbiturate does not eliminate the effect of indomethacin ...
Indomethacin markedly blunts cerebral perfusion and ...
Indomethacin reduced MCAv mean and impaired cognition slightly; however, no clear association was evident in younger or older adults.
Differential effects of ibuprofen and indomethacin on ...
Indomethacin significantly reduces cerebral blood flow soon after administration, resulting in a parallel increase in oxygen extraction and arterial lactate.
A Review of its Role in the Management of Traumatic Brain ...
Indomethacin should only be considered as an experimental therapy for refractory intracranial hypertension in TBI patients.
Indomethacin: Uses, Interactions, Mechanism of Action
In a study of healthy individuals, acute oral and intravenous indometacin therapy resulted in a transiently diminished basal and CO2 stimulated cerebral blood ...
Indomethacin Capsules, USP 25 mg Rx only WARNING
In one study after one week of treatment with orally administered indomethacin, this effect on basal cerebral blood flow had disappeared. The clinical ...
Indomethacin: uses, dosing, warnings, adverse events, ...
Indomethacin is used orally or rectally for anti-inflammatory and analgesic effects in the symptomatic treatment of moderate to severe rheumatoid arthritis.
Indomethacin - StatPearls - NCBI Bookshelf - NIH
Indomethacin's high lipid solubility facilitates easy crossing of the blood-brain barrier. Additionally, it achieves high concentrations in ...
NCT04265053 | Human Cerebral Blood Flow Regulation
Indomethacin is used to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt. Drug : Ganirelix Acetate.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.